{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:20:02Z","timestamp":1788841202442,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00487"],"award-info":[{"award-number":["PI20\/00487"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01430"],"award-info":[{"award-number":["PI21\/01430"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In chronic kidney disease, the accumulation of protein-bound uremic toxins (PBUTs), such as hippuric acid (HA), p-cresyl sulfate (PCS) and indoxyl sulfate (IS), contributes to systemic toxicity and organ dysfunction. These toxins bind to plasma proteins, primarily albumin, rendering them resistant to clearance by conventional dialysis. This study hypothesizes that loop diuretics, particularly torasemide and furosemide, can displace PBUTs from their albumin-binding sites, increasing their free fraction and enhancing their removal during hemodialysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This pilot multicenter crossover study included 17 anuric hemodialysis patients recruited from two hospitals. Participants underwent sequential treatment with furosemide and torasemide, each phase separated by a 1-week washout period. Plasma concentrations of HA, PCS and IS were measured pre- and post-dialysis during baseline (no diuretics) and diuretic treatment phases using high-performance liquid chromatography coupled with tandem mass spectrometry. Changes in pre- and post-dialysis toxin levels were evaluated across treatment phases. Repeated measures analysis of variance assessed the effect of each diuretic treatment on toxin levels and clearance rates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Both loop diuretics increased the free fraction and clearance of PBUTs compared with baseline. Torasemide demonstrated higher efficacy in enhancing the clearance of HA (76.8%) compared with furosemide (63.2%) and baseline (57.3%). For PCS, furosemide achieved greater reductions (66.3%) than torasemide (61.8%) and baseline (24%). Indoxyl sulfate clearance increased significantly with both diuretics (59.1% for furosemide and 58.8% for torasemide) compared with baseline (26.2%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study demonstrates that loop diuretics, especially torasemide, can enhance the clearance of PBUTs during hemodialysis. Their use mobilizes PBUTs from tissue stores and increases their dialyzability. These findings warrant further investigation in larger, long-term studies to validate the efficacy and clinical benefits of this approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf195","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T09:17:08Z","timestamp":1749892628000},"source":"Crossref","is-referenced-by-count":5,"title":["Loop diuretics in anuric hemodialysis patients for the clearance of protein-bound uremic toxins"],"prefix":"10.1093","volume":"18","author":[{"given":"Didier","family":"S\u00e1nchez-Ospina","sequence":"first","affiliation":[{"name":"Servicio An\u00e1lisis Cl\u00ednicos, Hospital Universitario de Burgos , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Romero-Cote","sequence":"additional","affiliation":[{"name":"Laboratory of Renal pathology and diabetes, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Autonoma University , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Criado-Bellido","sequence":"additional","affiliation":[{"name":"IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Universidad Autonoma de Madrid Department of Nephrology and Hypertension, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Saez-Calero","sequence":"additional","affiliation":[{"name":"Burgos University Hospital Department of Nephrology, , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badawi","family":"Hijazi-Prieto","sequence":"additional","affiliation":[{"name":"Burgos University Hospital Department of Nephrology, , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Delgado-Cuesta","sequence":"additional","affiliation":[{"name":"Servicio An\u00e1lisis Cl\u00ednicos, Hospital Universitario de Burgos , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Herrera-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Burgos University Hospital Department of Nephrology, , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalen","family":"Mujika-Marticorena","sequence":"additional","affiliation":[{"name":"Servicio An\u00e1lisis Cl\u00ednicos, Hospital Universitario de Burgos , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Gonzalez-Parra","sequence":"additional","affiliation":[{"name":"Laboratory of Renal pathology and diabetes, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Autonoma University , Madrid ,","place":["Spain"]},{"name":"IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Universidad Autonoma de Madrid Department of Nephrology and Hypertension, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jesus","family":"Izquierdo-Ortiz","sequence":"additional","affiliation":[{"name":"Burgos University Hospital Department of Nephrology, , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6604-3327","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Mas-Fontao","sequence":"additional","affiliation":[{"name":"Laboratory of Renal pathology and diabetes, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Autonoma University , Madrid ,","place":["Spain"]},{"name":"Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM) , Madrid ,","place":["Spain"]},{"name":"Faculty of Medicine and Biomedicine, Universidad Alfonso X el Sabio (UAX) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"2025071605162542200_bib1","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1681\/ASN.2011121175","article-title":"Normal and pathologic concentrations of uremic toxins","volume":"23","author":"Duranton","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025071605162542200_bib2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/nu9050489","article-title":"Nutrients turned into toxins: microbiota modulation of nutrient properties in chronic kidney disease","volume":"9","author":"Fernandez-Prado","year":"2017","journal-title":"Nutrients"},{"key":"2025071605162542200_bib3","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int"},{"key":"2025071605162542200_bib4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5935\/0101-2800.20140033","article-title":"The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins","volume":"36","author":"Barreto","year":"2014","journal-title":"J Bras Nefrol"},{"key":"2025071605162542200_bib5","doi-asserted-by":"publisher","first-page":"100299","DOI":"10.1016\/j.impact.2021.100299","article-title":"Protein-bound uremic toxins (PBUTs) in chronic kidney disease (CKD) patients: production pathway, challenges and recent advances in renal PBUTs clearance","volume":"21","author":"Daneshamouz","year":"2021","journal-title":"NanoImpact"},{"key":"2025071605162542200_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/bdd.1834","article-title":"Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate","volume":"34","author":"Viaene","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"2025071605162542200_bib7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3390\/jcm13051428","article-title":"Displacing the burden: a review of protein-bound uremic toxin clearance strategies in chronic kidney disease","volume":"13","author":"S\u00e1nchez-Ospina","year":"2024","journal-title":"J Clin Med"},{"key":"2025071605162542200_bib8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/toxins11070389","article-title":"A bifunctional adsorber particle for the removal of hydrophobic uremic toxins from whole blood of renal failure patients","volume":"11","author":"Sternkopf","year":"2019","journal-title":"Toxins"},{"key":"2025071605162542200_bib9","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1021\/jp9059517","article-title":"Binding of p-cresylsulfate and p-cresol to human serum albumin studied by microcalorimetry","volume":"114","author":"Berg\u00e9-Lefranc","year":"2010","journal-title":"J Phys Chem B"},{"key":"2025071605162542200_bib10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2215\/CJN.06100710","article-title":"Contribution of residual function to removal of protein-bound solutes in hemodialysis","volume":"6","author":"Marquez","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025071605162542200_bib11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/ndt\/gfz042","article-title":"Contribution of \u201cclinically negligible\u201d residual kidney function to clearance of uremic solutes","volume":"35","author":"Toth-Manikowski","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025071605162542200_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/toxins14030177","article-title":"The interplay between uremic toxins and albumin, membrane transporters and drug interaction","volume":"14","author":"da Cunha","year":"2022","journal-title":"Toxins"},{"key":"2025071605162542200_bib13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1248\/bpb.18.1755","article-title":"Characterization of binding site of uremic toxins on human serum albumin","volume":"18","author":"Sakai","year":"1995","journal-title":"Biol Pharm Bull"},{"key":"2025071605162542200_bib14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41598-018-37195-1","article-title":"In silico comparison of protein-bound uremic toxin removal by hemodialysis, hemodiafiltration, membrane adsorption, and binding competition","volume":"9","author":"Maheshwari","year":"2019","journal-title":"Sci Rep"},{"key":"2025071605162542200_bib15","doi-asserted-by":"publisher","first-page":"23389","DOI":"10.1038\/srep23389","article-title":"Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an in vitro human whole blood study","volume":"6","author":"Tao","year":"2016","journal-title":"Sci Rep"},{"key":"2025071605162542200_bib16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00003495-199100413-00005","article-title":"The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics","volume":"41","author":"Knauf","year":"1991","journal-title":"Drugs"},{"key":"2025071605162542200_bib17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199834010-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of torasemide","volume":"34","author":"Knauf","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"2025071605162542200_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2036.1995.tb00784.x","article-title":"Drugs for pH control in upper gastrointestinal bleeding","volume":"9","author":"Brunner","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"2025071605162542200_bib19","first-page":"176","article-title":"Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver","volume":"38","author":"Brunner","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"2025071605162542200_bib20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/clpt.1980.148","article-title":"Furosemide in patients with heart failure: shift in dose-response curves","volume":"28","author":"Brater","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"2025071605162542200_bib21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF00194966","article-title":"Pharmacokinetics of torasemide and its metabolites in end-stage renal disease","volume":"47","author":"Kr\u00e4mer","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"2025071605162542200_bib22","first-page":"381","article-title":"Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (Part I)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"2025071605162542200_bib23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ki.2013.154","article-title":"Numerous protein-bound solutes are cleared by the kidney with high efficiency","volume":"84","author":"Sirich","year":"2013","journal-title":"Kidney Int"},{"key":"2025071605162542200_bib24","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1681\/ASN.2014121193","article-title":"Tubular secretion in CKD","volume":"27","author":"Suchy-Dicey","year":"2016","journal-title":"J Am Soc Nephol"},{"key":"2025071605162542200_bib25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/toxins16070298","article-title":"Residual kidney function in hemodialysis: its importance and contribution to improved patient outcomes","volume":"16","author":"Obi","year":"2024","journal-title":"Toxins"},{"key":"2025071605162542200_bib26","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/jpm11111118","article-title":"Gut microbiome profiling uncovers a lower abundance of Butyricicoccus in advanced stages of chronic kidney disease","volume":"11","author":"Gryp","year":"2021","journal-title":"J Pers Med"},{"key":"2025071605162542200_bib27","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.ekir.2022.07.003","article-title":"Efficacy, safety, and tolerability of oral furosemide among patients receiving hemodialysis: a pilot study","volume":"7","author":"Flythe","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025071605162542200_bib28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/sj.ki.5001640","article-title":"Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis","volume":"70","author":"Evenepoel","year":"2006","journal-title":"Kidney Int"},{"key":"2025071605162542200_bib29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.ajkd.2005.05.016","article-title":"Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients","volume":"46","author":"Bammens","year":"2005","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf195\/63491020\/sfaf195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/7\/sfaf195\/63491020\/sfaf195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/7\/sfaf195\/63491020\/sfaf195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:16:33Z","timestamp":1752657393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf195\/8162725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf195","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,14]]},"article-number":"sfaf195"}}